TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29382400
Drug: Ethanol (61%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (61% w/v) plus chlorhexidine gluconate (1.0% solution)
Study: 22393376
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily for 4 weeks
Study: 24580390
Drug: 15 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg/kg morphine with 0.125% levobupivacaine
Study: 24580390
Drug: 7.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg/kg morphine with 0.125% levobupivacaine
Study: 7929871
Drug: Zopolrestat (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopolrestat (dose range 50 to 1200 mg)
Study: 26683485
Drug: Paediatric chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric chemotherapy protocol (UKALL2003)
Study: 1677545
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion during isoflurane-narcotic-nitrous oxide anesthesia
Study: 1677545
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion during halothane-narcotic-nitrous oxide anesthesia
Study: 1677545
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion during narcotic-nitrous oxide anesthesia
Study: 1677545
Drug: Recovery index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery index after termination of vecuronium infusion
Study: 6139572
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal peptide (VIP) administered intravenously at 6 pmol/kg/min for 15 min
Study: 22527786
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously
Study: 25990255
Drug: 1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol/kg of KHCO3 daily for 3 months
Study: 25990255
Drug: 1.5 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mmol/kg of KHCO3 daily for 3 months
Study: 24483776
Drug: Self-reported recall
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported recall of weight monitoring adherence (daily or more frequent weighing)
Study: 9098478
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in women Ct positive but affected by PID
Study: 24428466
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily
Study: 24428466
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily
Study: 23406994
Drug: MA (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (160 mg po, bid) plus thalidomide (50 mg po, bid)
Study: 23406994
Drug: MA (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (160 mg po, bid) alone
Study: 15181652
Drug: Kava extract
Normalized name: Kava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava extract (300 mg; p.o.)
Study: 2017519
Drug: mCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.5 mg/kg)
Study: 3568947
Drug: pirenzepine (PIR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine (PIR), 50 mg
Study: 27064778
Drug: Lateral infrapatellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral infrapatellar injection site
Study: 17975480
Drug: Nonselective beta‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective beta‐adrenergic blockers
Study: 18281407
Drug: STEPPS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEPPS plus treatment as usual
Study: 12205648
Drug: Simvastatin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (up to 80mg daily)
Study: 8682007
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg daily
Study: 7142740
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid formulated in a series of solutions and gels at 90% saturation
Study: 18096708
Drug: Procalcitonin-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided therapy
Study: 16467656
Drug: Aliskiren (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (300 mg)
Study: 17322141
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg)
Study: 17428017
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg gabapentin capsule
Study: 3602221
Drug: Unilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ECT two times weekly
Study: 3602221
Drug: Unilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ECT three times weekly
Study: 30740964
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral medroxyprogesterone acetate (MPA) 500 mg/day / levonorgestrel-intrauterine system (LNG-IUS)
Study: 23399553
Drug: Fluticasone 440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 440 mcg twice daily
Study: 19514651
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin 0.1 mg)
Study: 28850308
Drug: Curcumin 500
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500 mg twice daily
Study: 19536884
Drug: PF‐3512676 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐3512676 40 mg + DTIC (850 mg/m(2))
Study: 19536884
Drug: DTIC (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (850 mg/m(2)) alone
Study: 19536884
Drug: PF‐3512676 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐3512676 10 mg
Study: 19536884
Drug: PF‐3512676 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐3512676 40 mg
Study: 16770284
Drug: 1000 kcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 kcal daily intravenous supplement for 3 days, followed by a 400 kcal oral nutritional supplement for 7 days
Study: 2882083
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant ('Surfactant TA') 100 mg/kg surfactant phospholipid
Study: 25130401
Drug: Lumiliximab in
Normalized name: Lumiliximab
DrugBank: Lumiliximab (DB06162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiliximab in combination with fludarabine, cyclophosphamide and rituximab (FCR)
Study: 19557400
Drug: Improved quality
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved quality of discharge summary with clinical pharmacists reviewing and providing feedback on the medication report before discharge.
Study: 19557400
Drug: Patients using
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using the ApoDos medication dispensing system.
Study: 28862032
Drug: Heparin pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin pre-treatment
Study: 28862032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin pre-treatment)
Study: 28160513
Drug: Pru p
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pru p 3 sublingual immunotherapy (SLIT)
Study: 11104556
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent carboplatin
Study: 11372583
Drug: Intracutaneous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracutaneous indomethacin (10 micrograms/ml and 100 micrograms/ml)
Study: 11372583
Drug: Peroral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral indomethacin (100 mg)
Study: 11372583
Drug: Mepyramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepyramine (10 micrograms/ml)
Study: 11372583
Drug: Peroral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral zafirlukast (40 mg)
Study: 9844453
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Metronidazole (500 mg/12 h)
Study: 9844453
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Amoxicillin (1 g/12 h)
Study: 7862925
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) 0.4 mg/kg
Study: 2510268
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg b.d.
Study: 25925487
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality intervention protocol for pelvic floor muscle training (30 min, twice a week, total of 10 sessions)
Study: 16681477
Drug: 20-mg tadalafil
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg tadalafil taken on demand
Study: 2892392
Drug: Nizatidine 75
Normalized name: nizatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 75 mg
Study: 9236562
Drug: Nizatidine 25
Normalized name: nizatidine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 25 mg
Study: 488880
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g Paromomycin administered on each of the two preoperative days combined with mechanical cleansing of the intestine
Study: 23709409
Drug: Brain-directed nutrients
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain-directed nutrients (BDNs) including fish oil, a high-potency multiple vitamin/mineral supplement, and a brain-enhancement supplement.
Study: 21216328
Drug: Methoxyflurane (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxyflurane (3 ml via hand-held inhaler)
Study: 19638968
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water consumption (2 l) before colonoscopy
Study: 19638968
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water consumption (2 l) before colonoscopy
Study: 12885699
Drug: Sibutramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine treatment
Study: 6315789
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal cream (after clinical cure)
Study: 21744011
Drug: Betaine plus
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine plus Creatine (BET+CR; 2+20 g/day)
Study: 21744011
Drug: Betaine (BET;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (BET; 2 g/day)
Study: 19389877
Drug: Dapoxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 60 mg
Study: 11988597
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 to 300 mg/d)
Study: 11988597
Drug: AF patients
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF patients on no antithrombotic therapy
Study: 6102837
Drug: Cimetidine, 4
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 4 x 400 mg
Study: 30998824
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (600 mg)
Study: 30998824
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (loading dose 8 mg/kg; maintenance dose 6 mg/kg)
Study: 25827291
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 40mg/m2 (Arm C)
Study: 25827291
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 40mg/m2 and gemcitabine 125mg/m2 (Arm CG)
Study: 9603534
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic prophylaxis
Study: 15157383
Drug: Anticholinesterase drugs
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinesterase drugs and steroids treatment
Study: 6294732
Drug: Intramuscular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo
Study: 28501100
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg intravenous)
Study: 25676084
Drug: Enhanced external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced external counterpulsation (EECP) therapy
Study: 17877952
Drug: Neoadjuvant antihormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant antihormonal therapy (tamoxifen and aromatase inhibitors)
Study: 17877952
Drug: Tamoxifen as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen as primary treatment
Study: 7665538
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of clomipramine
Study: 7665538
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of clomipramine
Study: 795375
Drug: Josamycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (2 g daily for 7 days)
Study: 795375
Drug: Erythromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2 g daily for 7 days)
Study: 29898836
Drug: Additional antiplatelet
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional antiplatelet therapy
Study: 16229114
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 16 mg
Study: 7890074
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACE inhibitor)
Study: 7890074
Drug: Captopril, 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 6.25 mg orally twice daily for 4 days
Study: 2095164
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 81 mval/day MgSO4 for 3 days
Study: 18214709
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV cyclophosphamide (LD-CYC) 500 mg/dose for six fortnightly pulses (cumulative dose 3 g) followed by azathioprine (AZA)
Study: 18214709
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV cyclophosphamide (HD-CYC) maximum of 1 g/dose for six monthly pulses followed by two quarterly pulses, followed by azathioprine (AZA)
Study: 18214709
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV cyclophosphamide (HD-CYC)
Study: 26777322
Drug: Prasugrel 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 30 mg
Study: 16769598
Drug: Prasugrel 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 75 mg
Study: 15446552
Drug: High-dose ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ifosfamide and etoposide combination or carboplatin combination
Study: 15446552
Drug: High-dose ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ifosfamide and doxorubicin
Study: 11376923
Drug: Methadone tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone tapering plus amantadine (200-300 mg per day)
Study: 8357779
Drug: Cicletanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (200 mg)
Study: 29332237
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of maltodextrin (placebo)
Study: 27567966
Drug: Combined nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined nicotine replacement therapy/placebo and contingency management for attendance/abstinence
Study: 20876621
Drug: Nebulized colistimethate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized colistimethate sodium (CMS) equivalent to 75 mg of colistin base in 4 mL of NSS
Study: 11015164
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide per day
Study: 30109735
Drug: Interdisciplinary programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary programme based on healthy eating, physical exercise, and cognitive behavioural therapy
Study: 24323034
Drug: combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined androgen blockade with luteinizing hormone‐releasing hormone agonist and bicalutamide (Control)
Study: 22360332
Drug: 2% L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% L-carnitine applied topically for 3 weeks
Study: 22360332
Drug: 0.5% or
Normalized name: PHENOL 0.5% ORAL SPRAY TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% or 1% L-carnitine in vitro
Study: 18382819
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy group (n = 15)
Study: 1815973
Drug: Dihydroergotamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 0.1 mg intravenously
Study: 1815973
Drug: Dihydroergotamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 0.5 mg intravenously
Study: 1815973
Drug: Dihydroergotamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (all doses)
Study: 6292803
Drug: Doxycycline 300
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 300 mg orally
Study: 6292803
Drug: Pivmecillinam 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 600 mg orally
Study: 27502805
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology treatment
Study: 15259283
Drug: E2/NETA (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (estradiol 2 mg plus norethisterone acetate 1 mg)
Study: 7487618
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate (0.2%) given topically twice daily for 1 week
Study: 28422874
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at 0.4 μg/kg/h
Study: 25039244
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% potassium hydroxide (KOH) solution
Study: 17445898
Drug: Preoperative sub‐Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative sub‐Tenon's capsule injection of 3 ml of 0.75% ropivacaine
Study: 17445898
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sub‐Tenon's capsule injection of 3 ml of saline)
Study: 16113430
Drug: Fluticasone (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (inhaled corticosteroid)
Study: 12575211
Drug: First aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC)
Study: 12575211
Drug: Second aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and 1 x 10(6) units of aprotinin for intravenous bolus)
Study: 12575211
Drug: Amrinone combined
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrinone combined with aprotinin group (3 x 10(6) units of aprotinin added to the priming solution of ECC and amrinone bolus of 1 mg/kg followed by maintenance of 8 micrograms/kg.min)
Study: 9613383
Drug: Isovolaemic haemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolaemic haemodilution therapy (IHT) for 6 weeks with venesection and volume replacement using hydroxyethylstarch, targeting a haematocrit of 35%.
Study: 7852229
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intramuscular hepatitis B vaccine (2 micrograms at first, followed by 1 microgram each at 1, 2, and 6 months)
Study: 7852229
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose intramuscular hepatitis B vaccine (10 micrograms each at 0, 1, and 6 months)
Study: 25713462
Drug: Integrated neurocognitive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated neurocognitive therapy (INT)
Study: 20683104
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg b.d.)
Study: 17224034
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administered in the wound
Study: 10535234
Drug: Exposure-based contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based contingency management (CM) treatment
Study: 7024200
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group with enhanced commitment (contracts signed by participant and at least one friend, relative, or peer)
Study: 25528325
Drug: School-Located Vaccination
Normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-Located Vaccination Clinics (SLVCs) for Tdap vaccine
Study: 21883103
Drug: Structured exercise
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured exercise intervention (three weekly supervised sessions in a fitness center)
Study: 15221991
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg) plus 5-fluorouracil/leucovorin (5-FU/LV)
Study: 12149107
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of tap water
Study: 1102383
Drug: Loesferron effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loesferron effervescent iron tablet
Study: 30799502
Drug: IVO +
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVO + IM discontinuation for patients with MRD‐CR
Study: 27129119
Drug: GSK2485852 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2485852 70 mg
Study: 22944150
Drug: Monthly e-newsletters
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly e-newsletters